Oncologic Applications of Photodynamic Therapy, Including Barrett’s Esophagus
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity criteria and coverage stance for non-dermatologic oncologic uses of photodynamic therapy (PDT), including treatment of Barrett’s esophagus with high-grade dysplasia, for Blue Cross Blue Shield of North Carolina members and treating providers.
No material clinical or coverage changes in this revision.
Coverage Criteria
Medically necessary indications
Covered when the medical criteria and guidelines noted below are met and PDT is medically necessary for the specified oncologic indications:
Covered indications
- Palliative treatment of obstructing esophageal cancer.
- Palliative treatment of obstructing endobronchial lesions.
- Treatment of early-stage non-small-cell lung cancer in individuals who are ineligible for surgery and radiotherapy; use supported by case series reporting complete response rates of 72%–100% in this small population.
- Treatment of high-grade dysplasia in Barrett’s esophagus (PDT plus proton pump inhibitor shown to increase response and reduce progression versus PPI alone, though with higher complication rates such as strictures).
- Palliative treatment of unresectable cholangiocarcinoma when used in conjunction with biliary stenting (PDT plus stenting associated with improved duct patency and progression-free survival in small RCTs/observational studies).
Evidence-based rationale for covered indications
Evidence summaries supporting coverage decisions:
Oncologic applications of photodynamic therapy (PDT) that are not explicitly listed as medically necessary in this policy are considered investigational and are not covered by BCBSNC. This exclusion includes other malignancies and situations not specified among the policy’s covered indications.
Use of PDT for malignancies other than the indications defined as medically necessary in this policy, and the use of PDT for Barrett’s esophagus without associated high-grade dysplasia, is considered investigational and is therefore not medically necessary and not covered.
Billing and Coding
Provider Actions and Requirements
Palliative radiation preferred when feasible
For palliation of obstructing esophageal or endobronchial lesions, palliative radiation is preferred over photodynamic therapy when it is feasible to deliver radiation.
Submit medical records when requested
BCBSNC may request medical records to determine medical necessity; letters of support or explanation can be helpful but are not sufficient documentation unless they include all specific information needed to make the determination.
Investigational uses are denied
Requests for photodynamic therapy for oncologic applications not explicitly listed as medically necessary are considered investigational and are not covered; this includes use for Barrett’s esophagus without associated high-grade dysplasia.
Background
Photodynamic therapy employs a photosensitizing agent (for example, porfimer sodium or oral 5‑aminolevulinic acid (5‑ALA)) followed by exposure to light at a specific wavelength to produce cellular injury in targeted tissue. Porfimer sodium is administered intravenously approximately 48 hours before light exposure and causes prolonged photosensitivity; recipients must avoid bright light for approximately 30 days. Oral 5‑ALA is given a few hours before the procedure and topical formulations are used in dermatologic indications (addressed separately).
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.